Sector News

ARIAD announces reduction in workforce

March 30, 2016
Life sciences

ARIAD Pharmaceuticals, Inc. (ARIA) today announced that it is reducing approximately 25 percent of its headquarter positions.

The reduction includes approximately 90 positions in the U.S. and Europe. No customer-facing positions within ARIAD’s commercial or medical affairs organizations are included in this action.

This reduction in workforce is one of five key areas of ARIAD’s ongoing strategic review. In addition to the decision announced today, the review also includes an evaluation of commercial maximization initiatives, geographical presence, R&D portfolio, and business development opportunities to support the overall strategic direction. ARIAD plans to provide further details on the progress of the strategic review, which is aimed at increasing patient and shareholder value, in the second quarter of 2016.

“The decision to reduce the Company’s workforce has been extremely difficult, but we believe that it is a necessary step to invest in the promising growth potential of both Iclusig® and brigatinib and, ultimately, to further enable our orphan oncology medicines to reach cancer patients in desperate need,” said Paris Panayiotopoulos, president and chief executive officer of ARIAD. “I would like to express my sincere gratitude to the talented employees affected today, and we will do our utmost to ensure everyone is treated with fairness and respect.”

Source: ARIAD

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.